Country: United States
Language: English
Source: NLM (National Library of Medicine)
QUINUPRISTIN (UNII: 23OW28RS7P) (QUINUPRISTIN - UNII:23OW28RS7P), DALFOPRISTIN (UNII: R9M4FJE48E) (DALFOPRISTIN - UNII:R9M4FJE48E)
Pfizer Laboratories Div Pfizer Inc
QUINUPRISTIN
QUINUPRISTIN 150 mg in 5 mL
INTRAVENOUS
PRESCRIPTION DRUG
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Synercid and other antibacterial drugs, Synercid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Synercid is indicated in adults for the treatment of the following infections when caused by susceptible strains of the designated microorganisms. Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin susceptible ) or Streptococcus pyogenes . (See CLINICAL STUDIES. ) Synercid is contraindicated in patients with known hypersensitivity to Synercid , or with prior hypersensitivity to other streptogramins (e.g. , pristinamycin or virginiamycin).
Synercid is supplied as a sterile lyophilized pyrogen-free preparation in single-dose 10 mL type I glass vials with gray elastomeric closure, and aluminum seal with a dark blue flip-off cap for the 500 mg vial.
New Drug Application
SYNERCID- QUINUPRISTIN AND DALFOPRISTIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PFIZER LABORATORIES DIV PFIZER INC ---------- SYNERCID I.V. (QUINUPRISTIN AND DALFOPRISTIN FOR INJECTION) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SYNERCID and other antibacterial drugs, SYNERCID should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SYNERCID (quinupristin and dalfopristin powder for injection) I.V., a streptogramin antibacterial agent for intravenous administration, is a sterile lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin (derived from pristinamycin I) and dalfopristin (derived from pristinamycin IIA) in the ratio of 30:70 (w/w). Quinupristin is a white to very slightly yellow, hygroscopic powder. It is a combination of three peptide macrolactones. The main component of quinupristin (> 88.0%) has the following chemical name: N-[(6_R_,9_S_,10_R_,13_S_,15_aS_,18_R_,22_S_,24_aS_ )-22-[_p_- (dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl-5,8,12,15,17,21,24- heptaoxo-13-phenyl-18-[[(3_S_ )-3-quinuclidinylthio] methyl]-12_H_-pyrido[2,1-_f_ ]pyrrolo- [2,1-_l_ ][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide. The main component of quinupristin has an empirical formula of C H N O S, a molecular weight of 1022.24 and the following structural formula: Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical name for dalfopristin is: (3_R_,4_R_,5_E_,10_E_,12_E_,14_S_,26_R_,26a_S _)-26-[[2-(diethylamino)ethyl]sulfonyl]- 8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3_H_-21,18- nitrilo-1_H_,22_H_-pyrrolo[2,1-_c_ ][1,8,4,19]-dioxadiazacyclotetracosine-1,7,16,22(4_H_,17_H _)- tetrone. ® ® 53 67 9 10 Dalfopristin has an empirical formula of C H N O S, a molecular weight of 690.85 and the following structural formula: CLINICAL PHARMACOLOGY PHARMACOKINETICS Quinupristin and dalfopristin are the m Read the complete document